
Sustainability
Planet
Minimizing environmental footprint
Camurus strives to conduct a sustainable business where environmental and climate considerations are integrated into the company’s decisions. Together with suppliers and other stakeholders, the company works to minimize its operational and product-related impact throughout the entire value chain. This includes the development of circular solutions and avoiding incidents with impact on the environment.
Material aspects
Climate change
Camurus’ greatest climate impact is in scope 3 (estimated close to 80 percent), which is the emissions that occur upstream and downstream in the value chain. We actively work to minimize the company’s greenhouse gas emissions throughout the value chain. In 2023, an environmental mapping of the value chain was initiated with the aim of calculate and reduce the company’s impact, a work that continues in 2024.
Environmental impact (incl. pharmaceuticals in the environment
We strive to minimize the environmental impact of our products as much as possible, both related to water consumption, waste, use of resources and chemicals, energy flows etc. At Camurus, we work closely with our contract manufacturer to prevent the release of pharmaceuticals into soil or water.
Our goals
- Reduce scope 1 and 21 greenhouse gas emissions by at least 50%2 by 2035
- Reduce selected scope 33 greenhouse gas emissions by at least 40%2 by 2035
- Net zero greenhouse gas emissions (scope 1, 2 and 3) by 20454
- From 2024 onwards, at least 80% of the energy used within Camurus’ operations to come from renewable sources
- Transition from combustion engine cars to electric cars should be conducted as fast as possible5: From 2024 all new benefit cars are electric cars; Transition of job cars to electric cars in the Nordic countries by 2030; Transition of job cars to electric cars in other European countries by 2035; Transition of job cars to electric cars in all other countries by 2040
Transition plan
Camurus measures and is committed to reducing the company's emissions within Scope 1, 2 and 3. Learn about Camurus’ transition plan
Climate impact in the value chain
To reduce Camurus' total climate footprint across its own operations and the broader value chain – including production, distribution, and use of medicines - Camurus conducted a Greenhouse Gas Inventory in 2024. The emissions, reported in carbon dioxide equivalents (CO2e), are presented in the pie charts below.
* All emissions are reported in CO2 equivalents (CO2e).
Our achievements
30%
reduction of GHG emissions in air transports by use of renewable fuel SAF*
95%
reduction of GHG emissions in road transports by use of renewable biodiesel HVO*
*as at end December 2024, source: Annual Report 2024.
Reducing pharmaceuticals in the environment
Camurus strives to minimize the environmental impact of its products as much as possible and works closely with the company’s contract manufacturer to prevent the release of pharmaceuticals
into soil or water. Camurus’ products for e.g. the treatment of opioid dependence requires significantly lower amounts of active substance than comparable preparations for daily medication.
The contract manufacturer has well-developed safety procedures in place to prevent the release of pharmaceuticals, primarily from the active substance, into the environment. All process water is handled as hazardous waste and sent for disposal in accordance with applicable legislation, as well as contaminated containers and protective clothing.
In-depth data
For more in-depth data on focus area planet see Camurus' Annual Report 2024
References
- Scope 1 emissions include direct emissions from owned or controlled sources. Scope 2 emissions include indirect emissions from the generation of purchased energy.
- Compared to 2023.
- Scope 3 emissions include all indirect emissions (excluding scope 2) that occur in the company's supply chain, both upstream and downstream.
- The remaining greenhouse gas emissions that cannot be reduced will be offset in 2045 and beyond.
- Where technically feasible.